New insights into the role of NK cells in cancer immunotherapy by Salagianni, Maria et al.
© 2012 Landes Bioscience.
Do not distribute.
New insights into the role of NK cells
in cancer immunotherapy
Maria Salagianni, Constantin N. Baxevanis, Michael Papamichail and Sonia A. Perez*
Cancer Immunology and Immunotherapy Center; Saint Savas Cancer Hospital; Athens, Greece
Repetitive infusions of ex vivo expanded NK cells induced antitumor T-cell responses in a metastatic lung cancer mouse
model. These were further potentiated by Treg depletion. Thus the combination of NK cell-based immunotherapy with
other treatment modalities in the direction of adaptive response enhancement might promote long lasting antitumor
immunity.
NK cells are innate immune lymphocytes
which primarily function to lyse virally
infected cells and tumor cells and to
regulate innate and adaptive immune
responses through the production of
cytokines and chemokines.
1,2 The role of
NK cells in tumor immunosurveillance
and their potential for successful cancer
immunotherapy strategies is currently
established. The effectiveness of resting,
shortly activated or ex vivo expanded
autologous or allogeneic NK cell-based
immunotherapies is explored in preclinical
studies and clinical trials, for the treatment
of hematological malignancies and solid
tumors. The main issues addressed so far
in the clinical application of NK cells
referred to: (1) Overcoming inhibitory
signals, either by using allogeneic NK cells
or by blocking inhibitory receptors; (2) the
number of cells to be infused; and (3) the
in vivo persistence of the adoptively trans-
ferred NK cells in one single infusion
through preconditioning lymphodepletion
regimens and IL-2 co-administration.
The apparent goal of such approaches is
to achieve a clinical response by eliminating
as much as possible tumor cells by direct
NKcell-mediated killing.However effective
immunotherapy should elicit long lasting
memory immune responses in order to
prevent future relapse. Although NK cells
have been demonstrated to possess memory
against viruses,
3 there is no evidence yet
that this could also apply to the diversity of
tumor associated antigens (TAA).
Given that NK cells are part of an
integral immune network where the
function of each component population
may affect, positively or negatively, the
function of other immune cell popula-
tions, we explored the ability of NK
cells to induce memory anti-tumor T cell
immune responses in a metastatic lung
cancer mouse model.
Considering that adoptively transferred
NK cells would act, either indirectly,
through cross-talk with dendritic cells
(DC)
4 or directly, as antigen presenting
cells (APC),
4,5 to trigger priming of tumor-
specific T cells (Fig.1), we presumed
that repeated administrations of ex vivo
expanded NK cells would act as repeated
anti-tumor “vaccines.” Indeed, after four
weekly NK cell infusions we were able to
detect memory systemic T cell responses
against the syngeneic CT26 tumor cells,
either by in vitro testing of splenic T cell
reactivity or by rechallenging experimental
animals with tumor cells in another site of
the body.
6
To further optimize these anti-tumor
responses, we treated tumor-bearing ani-
mals with Ontak
1 (Denileukin Diftitox)
to eliminate regulatory T cells (Treg),
once, two days prior to the first NK cell
administration. Given that activated NK
cells are resistant to Treg-induced suppres-
sion, we hypothesized that elimination of
Tregs prior to T cell priming would lead
to more robust, long lasting immune
responses. Indeed, under these conditions
50% of the mice were cured; splenic T
cells produced more IFNc and exhibited
higher cytotoxicity and proliferation
against the CT26 cells in vitro; further-
more the growth rate of distal secondary
tumors was significantly delayed, com-
pared with mice treated with NK cells
alone.
6
Another important parameter to be
considered when applying cell-based
cancer immunotherapies is the ability of
the adoptively transferred cells to home to
the tumor sites. When considering solid
tumors, the persistence of the adoptively
transferred NK cells in the peripheral
blood is not informative about their effec-
tiveness to reach the tumor. This could
explain the recently published data from
a clinical trial of adoptive transfer of
autologous NK cells in patients with
metastatic melanoma or renal cell carci-
noma: although the adoptively transferred
NK cells appeared to persist in the
peripheral circulation of patients for at
least one week post transfer, and in some
patients for several months, no clinical
responses were observed.
7
In the case of our lung metastasis tumor
model, we found that about 60% of the
infused NK cells were present within the
lungs of the tumor-bearing animals three
days after their i.v. infusion and rapidly
declined to 25% after one week. Given
that activated NK cells are known to
infiltrate the lung tissue within minutes of
i.v. injection and can be retained by the
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tumor,
8 we can assume that only few NK
cells remained in the circulation.
The NK cells used in our preclinical
model were ex vivo expanded with IL-15
in the presence of hydrocortisone, a com-
bination that as we have previously
demonstrated, both in human and mice,
significantly accelerates NK cell prolifera-
tion, rendering these cells more resistant to
cytokine-induced cell death without com-
promising their functional potential.
6,9,10
Furthermore, NK cells expanded in the
presence of glucocorticoids (GC) express
high levels of CXCR3 and CXCR4,
6,10
indicating their increased potential to
home to the tumor sites.
Ourdataputforwardanadditional,sofar
unappreciated role for NK cells acting as
potent “cellular vaccines” inducing and/or
boosting endogenous adaptive antitumor
responses. In this context, NK cell-based
cellular therapy could be combined with
active and passive immunotherapies as well
as with other potential modalities of cancer
therapy including chemotherapy, radio-
therapy and biological therapies. This novel
biological role ascribes NK cells a central
position in the field of active cancer
immunotherapies in the context of perso-
nalized medicine. The exploitation of the
multi-talented NK cells against cancer is
still in its infancy and needs to be quickly
explored under a new perspective.
Figure1. Adoptive transfer of ex vivo activated and expanded NK cells can act as tumor-specific active immunotherapy, inducing long lasting anti-tumor
T cell responses. NK cells can be effectivelyactivated and expanded in vitro by cytokines in combination with GCs and/or other “stress” signals (a). Adoptively
transferred activated NK cells can lyse tumor cells thus leading to the release/ production of apoptotic bodies/TAAs (b). Such tumor-derived material will be
processed and presented to CD4 and CD8 T cells (i) directly, by the activated NK cells which express MHC class I and class II molecules (c) or (ii) indirectly,
through NK cell-mediated activation and polarization of DCs. This can be achieved by activated NK cell-produced cytokines (IFNc,T N F a, GM-CSF) (d) or by
direct cell-to-cell contact (i.e., NKp30-NKp30L) (e). Furthermore, activated NK cells expressing costimulatory molecules (e.g., CD86, OX40L, etc) can provide
efficient costimulation to T cells (through CD28, OX40, etc) (f). The concerted action of cytokines produced by the activated NKs and DCs (IFNc, IL-12) (g) will
support Th1 responses. The effective priming and restimulation of T cells by NK cells and/or DCs will induce the proliferation and differentiation of CD4
+ and
CD8
+ into effector/memory and central memory cells that can confer long lasting antitumor immunity (h). Improvement of these responses can be achieved
through inhibition of immunomodulatory mechanisms (e.g., Treg cell and MDSC elimination/ inhibition, anti-CTLA4 or anti-PD1 targeting etc) as applied in
other vaccination strategies (e.g., peptide vaccines, whole cell vaccines, DC-based vaccines etc.).
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